Zobrazeno 1 - 10
of 275
pro vyhledávání: ''
Autor:
Justin Buthorn, Noam Shomron, Fleur Cohen, Jean-François Emile, Roei D Mazor, Ofer Shpilberg, Omar Abdel-Wahab, Zahir Amoura, Eli L. Diamond, Ran Weissman, Benjamin H. Durham, Julien Haroche, Oshrat Hershkovitz-Rokah
Publikováno v:
Leukemia
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, ⟨10.1038/s41375-021-01472-2⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, ⟨10.1038/s41375-021-01472-2⟩
Erdheim–Chester disease (ECD) is characterized by excessive production and accumulation of histiocytes within multiple tissues and organs. ECD patients harbor recurrent mutations of genes associated with the RAS/RAF/MEK/ERK signaling pathway, parti
Autor:
Matthew S. Davids, Svitlana Tyekucheva, Vanessa Rai, David C. Fisher, James A. Lederer, Emily M. Thrash, Stacey M. Fernandes, Stephen P. Martindale, Alec Griffith, Jennifer R. Brown, Oreofe O. Odejide, Brandon Lee, Timothy Z. Lehmberg, Zixu Wang, Jon E. Arnason, Deepti Gadi, John-Hanson Machado, Philippe Armand, Alexander R. Vartanov
Publikováno v:
Leukemia. 36:723-732
Several PI3Kδ inhibitors are approved for the therapy of B cell malignancies, but their clinical use has been limited by unpredictable autoimmune toxicity. We have recently reported promising efficacy results in treating chronic lymphocytic leukemia
Autor:
Lisa B. Leypoldt, Markus Munder, Anne Marie Asemissen, Hartmut Goldschmidt, Carsten Bokemeyer, Raphael Lutz, Ullrich Graeven, Axel Benner, Britta Besemer, Rudolf Peceny, Manola Zago, Martin Görner, Mathias Hänel, Hans Salwender, Christoph Mann, Katja Weisel, Diana Tichy, Peter Staib, Yon-Dschun Ko, Anna Jauch, Hans Christian Reinhardt, Igor Wolfgang Blau
Publikováno v:
Leukemia, 36(3):885888
Autor:
Mohammad Reza Ahmadian, William L. Seibel, Yi Zheng, John P. Perentesis, Benjamin Mizukawa, Lisa M. Privette Vinnedge, Shailaja Hegde, Jose A. Cancelas, Oliver H.F. Krumbach, Yuan Lin, Mark Wunderlich, Nicolas Nassar, Anjelika Gasilina, Marcel Buchholzer, Mohammad Akbarzadeh
Publikováno v:
Leukemia. 36:637-647
Aberrant RHO guanine nucleotide exchange factor (RhoGEF) activation is chief mechanism driving abnormal activation of their GTPase targets in transformation and tumorigenesis. Consequently, a small-molecule inhibitor of RhoGEF can make an anti-cancer
Autor:
Charles S. Kuzma, Harry P. Erba, Mark R. Litzow, Steven Coutre, Scott E. Smith, Richard Stone, Amy S. Ruppert, Allison M Booth, Nancy L. Bartlett, Jeremy S. Abramson, John C. Byrd, Jennifer A. Woyach, Jennifer R. Brown, Richard F. Little, Richard A. Larson, Sumithra J. Mandrekar, Wei Ding, Sreenivasa Nattam, Carolyn Owen, Danielle M. Brander
Publikováno v:
Leukemia
Ibrutinib has superior progression-free survival compared with bendamustine plus rituximab (BR) in older CLL patients, however, differences in treatment duration, six monthly BR cycles versus continuous ibrutinib, complicate adverse event (AE) compar
Publikováno v:
Leukemia. 35:3044-3058
In the past decade, the available treatments for patients with acute lymphoblastic leukemia (ALL) have rapidly expanded, in parallel with an increased understanding of the genomic features that impact the disease biology and clinical outcomes. With t
Autor:
Angela Dispenzieri, Giampaolo Merlini, Arun Kumar, Ashutosh D. Wechalekar, Heather Landau, Vaishali Sanchorawala, Kihyun Kim, Efstathios Kastritis, Raymond L. Comenzo, Guohui Liu, Deborah Berg, Fiona Kwok, Stefan Schönland, Douglas V. Faller, Kenshi Suzuki
Publikováno v:
Leukemia
In the first phase 3 study in relapsed/refractory AL amyloidosis (TOURMALINE-AL1 NCT01659658), 168 patients with relapsed/refractory AL amyloidosis after 1–2 prior lines were randomized to ixazomib (4 mg, days 1, 8, 15) plus dexamethasone (20 mg, d
Autor:
Zeev Estrov, Prithviraj Bose, Varsha Gandhi, Jan A. Burger, Xuemei Wang, Naveen Garg, Rashmi Kanagal-Shamanna, Naveen Pemmaraju, Philip A. Thompson, Ana Ayala, Hagop M. Kantarjian, Koji Sasaki, Keyur P. Patel, Tapan M. Kadia, Alessandra Ferrajoli, Susan O'Brien, Elias Jabbour, Gautam Borthakur, Koichi Takahashi, Marina Konopleva, Wanda Lopez, Michael J. Keating, Wei Wang, William G. Wierda, Nitin Jain, Jeffrey L. Jorgensen, William Plunkett, Sa Wang
Publikováno v:
Leukemia. 35:3421-3429
Chemoimmunotherapy with combined fludarabine, cyclophosphamide and rituximab (FCR) has been an effective treatment for patients with chronic lymphocytic leukemia (CLL). We initiated a phase II trial for previously untreated patients with CLL with mut
Autor:
Ben L. Sanford, Martin S. Tallman, Richard F. Schlenk, Lucas J. Huebner, Jürgen Krauter, Hartmut Döhner, Maria Teresa Voso, Hubert Serve, Andrew H. Wei, Jorge Sierra, Bruno C. Medeiros, Dietger Niederwieser, Arnold Ganser, Insa Gathmann, Miguel A. Sanz, Joseph Brandwein, Rebecca B. Klisovic, Sergio Amadori, Christian Thiede, Thomas W. Prior, Richard A. Larson, Theo de Witte, Konstanze Döhner, Kristina Laumann, Richard Stone, Clara D. Bloomfield, Frederick R. Appelbaum, Guido Marcucci, Gerhard Ehninger, Ilene Galinsky, Susan Geyer, Sumithra J. Mandrekar
Publikováno v:
Leukemia, 35, 9, pp. 2539-2551
Leukemia, 35, 2539-2551
Leukemia
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Leukemia, 35, 2539-2551
Leukemia
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Contains fulltext : 237748.pdf (Publisher’s version ) (Closed access) The prospective randomized, placebo-controlled CALGB 10603/RATIFY trial (Alliance) demonstrated a statistically significant overall survival benefit from the addition of midostau
Autor:
Nikolaos Kanellias, Efstathios Kastritis, Konstantinos Stellos, Ioannis P. Trougakos, Maria Roussou, Kimon Stamatelopoulos, Nikolaos Makris, Despina Fotiou, Efstathios Manios, Ageliki Laina, Eleni-Dimitra Papanagnou, Georgios Georgiopoulos, Meletios A. Dimopoulos, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Maria Kotsopoulou, Evangelos Terpos, Maria Gavriatopoulou, Ioanna Dialoupi
Publikováno v:
Leukemia. 35:1418-1427
Carfilzomib (CFZ) improves survival in relapsed/refractory multiple myeloma but is associated with cardiovascular adverse events (CVAEs). We prospectively investigated the effect of CFZ on endothelial function and associations with CVAEs. Forty-eight